Clearside Biomedical Inc

Clearside Biomedical — Technical Presentation (October 2024)

32 slides from Clearside Biomedical's technical presentation, Oct 9, 2024

  1. Slide 1: ODYSSEY Phase 2b Clinical Trial Results

    ODYSSEY Phase 2b Clinical Trial Results October 9, 2024 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data in Wet AMD

    CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data in Wet AMD Enrolled Only Difficult-to-Treat Participants with Active Disease Achieved Primary Outcome Maintaining Stable BCVA with Repeat Dosing Compelling Intervention-Free Rates Abbreviation: Wet AMD = neovascular age-related macular degenera

  4. Slide 4: Delivering on the Potential of the Suprachoroidal Space

    Delivering on the Potential of the Suprachoroidal Space Proven Leader in Suprachoroidal Delivery with Thousands of Injections Performed in the Clinic Validated Suprachoroidal Space (SCS) Delivery with Approved Product, Multiple Collaborations, and Comprehensive IP Portfolio Differentiated SCS Clinic

  5. Slide 5: SCS Microinjector: Drug/Device Combination with Proven Versatility

    Abbreviations: UME = uveitic macular edema; DME = diabetic macular edema; DR = diabetic retinopathy; Sources: Clearside data on file | 1Kurup, et. al, Macula Society 2021 Safety of the Suprachoroidal Injection Procedure Utilizing SCS Microinjector® across Three Retinal Disorders. Well-accepted by re

  6. Slide 6: CLS-AX for the Treatment of Wet AMD

    CLS-AX for the Treatment of Wet AMD 6

  7. Slide 7: Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery

    Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery Axitinib High potency TKI with pan-VEGF receptor inhibition Proprietary CLS-AX Small Molecule Suspension Formulation Clearside formulation expertise Delivery via SCS Microinjector® Utilizes the same administration device as F

  8. Slide 8: A large and growing market opportunity

    A large and growing market opportunity Age-Related Macular Degeneration (AMD) is a Multi-Billion Dollar Market Sources: 1 Pennington, Katie L and DeAngelis, Margaret M, Eye and Vision, Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lip

  9. Slide 9: Positioning CLS-AX for Real-World Success

    Positioning CLS-AX for Real-World Success *Dosing regimens are per respective product labels | EYLEA® and EYLEA HD® are registered trademarks of Regeneron Pharmaceuticals| LUCENTIS® and VABYSMO® are registered trademarks of Genentech/Roche Maintain Vision & Reduce Office Visits Objective is to maint

  10. Slide 10: Phase 2b Topline Data Summary

    Phase 2b Topline Data Summary 10

  11. Slide 11: ODYSSEY Phase 2b Clinical Trial

    ODYSSEY Phase 2b Clinical Trial Trial Objectives: Evaluate safety, efficacy & duration of CLS-AX in participants with wet AMD Primary Outcomes: Mean change in BCVA from Baseline to Week 36; Safety & tolerability Secondary Outcomes: Other changes in visual function and retinal imaging, including CST;

  12. Slide 12: ODYSSEY Trial Design and Dosing Regimen

    * Disease Activity Assessments (DAA): Conducted at Week 12 through 32 to determine need for supplemental treatment. # In CLS-AX arm, following 3 loading doses of aflibercept and initial dose of CLS-AX at Baseline, participants will receive CLS-AX at least every 24 weeks unless more frequently requir

  13. Slide 13: CLS-AX Demonstrated Positive Efficacy Data in Wet AMD

    CLS-AX Demonstrated Positive Efficacy Data in Wet AMD Preliminary Topline Results Subject to Change Abbreviations: CST=Central Subfield Thickness Injection frequency reduction calculated by the average number of treatments 24 Weeks prior to Screening Visit as compared to Average number of treatments

  14. Slide 14: Intervention-Free Rates By Week Up to Each Visit

    Intervention–Free Rates By Week Up to Each Visit Two-Thirds of Participants Dosed with CLS-AX Reached Six Months Without Additional Treatment Calculation accounts for missed treatments; time of initial administration of study drug shown as month 0 on figure. Intervention-free rate calculation: if pa

  15. Slide 15: CLS-AX Demonstrated A Positive Safety Profile

    CLS-AX Demonstrated A Positive Safety Profile Preliminary Topline Results Subject to Change Safety Profile Excellent safety profile through 36 weeks including after mandatory re-dosing of CLS-AX at Week 24 No Serious Adverse Events (SAEs) No ocular SAEs or treatment-related SAEs: No drug or procedur

  16. Slide 16: Phase 2b Trial Participant Characteristics

    Phase 2b Trial Participant Characteristics 16

  17. Slide 17: ODYSSEY Trial Focused on Participants with Active Disease

    ODYSSEY Trial Focused on Participants with Active Disease Criteria for Supplemental Treatment Dosing Regimen Key Inclusion Criteria Disease Activity Assessments (DAA) Diagnosed with neovascular AMD (wet AMD) within 36 months of screening History of 2 to 4 anti-VEGF treatments in 6 months before scre

  18. Slide 18: Rapid Enrollment Demonstrates Investigator Interest in Suprachoroidal TKI Delivery

    Rapid Enrollment Demonstrates Investigator Interest in Suprachoroidal TKI Delivery Study Activity Date First Participant Randomized July 12, 2023 Last Participant Randomized December 13, 2023 SITES ACTIVATED PARTICIPANTS SCREENED PARTICIPANTS RANDOMIZED 32 60 158 Preliminary Topline Results Subject

  19. Slide 19: Demographics and Baseline Characteristics

    Demographics and Baseline Characteristics Characteristics CLS-AX Aflibercept Overall No. of participants 40 20 60 Mean age (range), years 76.9 (51-90) 80.3 (54-96) 78.0 (51-96) Women, no. (%) 25 (62.5) 14 (70.0) 39 (65.0) Race, no. (%) White Asian 37 (92.5) 3 (7.5) 20 (100) 0 57 (95.0) 3 (5.0) Media

  20. Slide 20: Phase 2b Topline Data Results

    Phase 2b Topline Data Results 20 Preliminary Topline Results Subject to Change

  21. Slide 21: ODYSSEY Confirmed the Ability to Administer Multiple Doses of CLS-AX

    ODYSSEY Confirmed the Ability to Administer Multiple Doses of CLS-AX with a Well-Tolerated Safety Profile Multi-Dosing Data CLS-AX Doses Received Including Baseline # Doses # Participants % of total enrolled (n=40) 1 2 5% 2 32 80% 3 6 15% Of the 40 participants in the trial: 32 received two doses of

  22. Slide 22: Stable Best Corrected Visual Acuity (BCVA) Over Weeks

    Stable Best Corrected Visual Acuity (BCVA) Over 36 Weeks ^Study drug administration for aflibercept participants given at Weeks 12, 20 and 28. Abbreviations: BCVA = best corrected visual acuity; SEM = standard error of the mean. P-value based on a 2-sample t-test between treatment groups . BCVA With

  23. Slide 23: Stable Central Subfield Retinal Thickness (CSRT) Over Weeks

    Stable Central Subfield Retinal Thickness (CSRT) Over 36 Weeks as Verified by Independent Reading Center ^Study drug administration for aflibercept participants given at Weeks 12, 20 and 28. Abbreviations: CSRT = central subfield retinal thickness – as reported by the reading center; SEM = standard

  24. Slide 24: More Participants May Have Been Intervention Free at Every Time Point

    More Participants May Have Been Intervention Free at Every Time Point if DAA Criteria Strictly Applied DAA = Disease Activity Assessment. Actual treatments compared to reading center confirmation. Active disease-free rate calculation: if participant had active disease at a study visit, those were re

  25. Slide 25: Consistently Reduced the Frequency of Injections

    24 Weeks Before and After CLS-AX Consistently Reduced the Frequency of Injections Comparison of Wet AMD Treatments Pre- and Post- Randomization Injection post Baseline includes re-dosing with CLS-AX and/or supplementary treatment with aflibercept. Injection frequency reduction calculated by the aver

  26. Slide 26: CLS-AX Demonstrated Positive Safety Profile

    CLS-AX Demonstrated Positive Safety Profile Abbreviations: AE = adverse event; SAE = serious adverse event; TEAE = treatment-emergent adverse event. No Ocular SAEs and No Treatment-Related SAEs Preliminary Topline Results Subject to Change No drug or procedure-related ocular SAEs No reported drug or

  27. Slide 27: Phase 3 Planning

    Phase 3 Planning 27 Phase 3 plans are in development and subject to change

  28. Slide 28: CLS-AX Flexible Dosing of a Biologic with the Duration of a TKI

    CLS-AX Flexible Dosing of a Biologic with the Duration of a TKI NDA = New Drug Application Goal for Label: Flexible Wet AMD Maintenance Dosing Regimen Between 3 Months and 6 Months *Phase 3 plans are in development and subject to change Next Steps Continue analysis of ODYSSEY results including exper

  29. Slide 29: Results Summary

    me) Results Summary CIDYSSEY 29

  30. Slide 30: CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data

    CLS-AX Now Phase 3 Ready Based on Positive ODYSSEY Data Preliminary Topline Results Subject to Change ✔︎ ✔︎ ✔︎ ✔︎ Achieved Primary Objective: Stable BCVA to Week 36 Difficult-to-treat Wet AMD participants with confirmed activity Compelling injection free rates up to 6 months Injection frequency redu

  31. Slide 31: Roger A. Goldberg, MD, MBA, Bay Area Retina Associates

    Roger A. Goldberg, MD, MBA Bay Area Retina Associates

  32. Slide 32: TM

    Nasdaq: CLSD TM

Clearside Biomedical — Technical Presentation (October 2024) on 6ix